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Abstract
Nanotechnology can provide a critical advantage in developing strategies for cancer management
and treatment by helping to improve the safety and efficacy of novel therapeutic delivery vehicles.
This paper reports the fabrication of poly(lactic acid-co-glycolic acid)/siRNA nanoparticles coated
with lipids for use as prostate cancer therapeutics made via a unique soft lithography particle
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molding process called PRINT (Particle Replication In Nonwetting Templates). The PRINT
process enables high encapsulation efficiency of siRNA into neutral and monodisperse PLGA
particles (32–46% encapsulation efficiency). Lipid-coated PLGA/siRNA PRINT particles were
used to deliver therapeutic siRNA in vitro to knockdown genes relevant to prostate cancer.
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Almost 30,000 men die every year with prostate cancer that becomes refractory to androgen
deprivation therapy.1 New therapeutic options and detection strategies are clearly needed.
Current research in nanomedicine is driven by the desire to create a methodology to
effectively deliver a range of biologically and therapeutically relevant cargos and to improve
the therapeutic index. Targeted cancer therapy by RNA interference (RNAi) is an approach
that can be used to silence genes in vivo by selectively targeting genes such as KIF11 (Eg5),
which encodes a motor protein that belongs to the kinesin-like protein family involved in
chromosome positioning and bipolar spindle formation during cell mitosis.
Small interfering RNAs (siRNA) are double-stranded RNA molecules approximately 21–25
base pairs (bp) long that act to inhibit gene expression through initiating enzymatic
degradation of a sequence-matched mRNA.2 siRNA-based therapeutic agents may provide a
promising way to overcome disease such as cancer by the natural process of RNA
interference.3–5 However, intracellular delivery of siRNA delivery is challenging because
siRNA is negatively charged and is prone to degradation in physiological conditions.
Therefore a non-toxic and non-immunogenic carrier is required to deliver the siRNA to its
action site, which will dramatically improve its clinical potential. An ideal carrier should be
able to protect siRNA, transport siRNA to target tissue, be internalized by target cells and
release siRNA to cytosol, but induce minimal toxicity or immune response.6 To address
these issues, carriers have been developed to deliver siRNA by combining cationic
polymers, peptides, and lipids with siRNA to form polyplexes and lipoplexes. 7–9
Conventional polyplex and lipoplex formulations are held together electrostatically and by
their bilayers; therefore requiring that these oppositely charged molecules remain complexed
while extracellularly followed by their disassembly once the complex is internalized into the
cell of choice. Both the serum and the extracellular matrix can lead to vector disassembly,
limiting their clinical applications. 10–13 Alternatively, polymeric NPs that contain nucleic
acids can be composed of solid polymer matrix such as poly(lactide-co-glycolide) (PLGA)
with the polycation encapsulated or attached to the particle surface.14 Nanoparticles
composed of PLGA are attractive for silencing applications because of their high stability,
low toxicity and the possibility of controlled release of the cargo, unfortunately the
knockdown efficiency is not as high as that observed with the polyplex systems.15 To date,
there have been no reports of intravenously delivered PLGA based carriers and there are
several reports of the in vitro delivery of siRNA by PLGA.16,17 On the other hand,
liposomes have proven to be highly efficient carriers of siRNA, especially to hepatocytes.18
Neutral lipids exhibit low toxicity, low immunogenicity and are easily produced. Liposomes
are also an attractive choice for gene delivery because they can be formulated as ~100 nm in
size and their by-products are biocompatible. Lipid encapsulation of the siRNA simply
involves mixing and incubation with a mixture of cationic and neutral lipid.19 Specific
delivery can be achieved by conjugating a targeting ligand to the lipid molecule and then
processing to form liposomes. The cationic charge can electrostatically complex with siRNA
to achieve a more robust construct, while the neutral lipids facilitate fusion to the host cell’s
membrane.20,21 Generally both liposomes and polymeric nanoparticles however are formed
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by self-assembly and so are not structurally robust. This represents a major disadvantage
from the standpoint of reproducibility, manufacturing, and drug administration.22
Hybrid NPs, formed by combining polymers and lipids, can be a robust drug delivery
platform with high drug encapsulation yields, tunable and sustained drug release profiles,
and excellent serum stabilities.23, 24 Polymeric NPs have been mixed with liposomes to form
lipid-polymer complexes such as lipoparticles where the lipid bilayer or lipid multilayer
fuses on the surface of polymeric NPs.25 These complexes usually require a two-step
formulation process: 1) development of polymeric NPs, and 2) encapsulation of polymeric
NPs within liposomes. Additionally, a platform to engineer sub-100 nm targeted lipid-
polymer hybrid NPs through a combination of nanoprecipitation and self-assembly has been
developed.26
We are interested in developing a process that enables the formation of a simple two-
component PLGA-siRNA nanoparticle system where the particle formation step does not
require a polyplex. Such a system, intrinsically resulting in particles with a negative zeta
potential with the siRNA protected as a cargo, could have its surface charge adjusted with
the addition of cationic lipids or polymers. Specifically, we have used a top-down
fabrication method, PRINT®, to generate highly uniform nanoparticles with a polymeric
core encapsulating the siRNA and a lipid shell enabling cellular uptake of the nanoparticle
formulation.27 We have shown that polylactic-co-glycolic acid (PLGA) particles containing
siRNA made with this approach can efficiently cause knockdown of gene expression in
various prostate cancer cell lines with minimum cytotoxicity.
The PRINT technique was used as described previously with a slight modification to
fabricate 80×320 nm monodisperse, siRNA-encapsulated PLGA particles followed by
coating with a cationic lipid.27 Non-spheical nanoparticles were specifically chosen for these
studies because needle-shaped polymer nanoparticles have been shown to be internalized
more readily than their spherical counterparts, causing a greater percentage of gene
knockdown in endothelial cells.28 Briefly, a pre-particle solution containing PLGA (85:15
lactic acid: glycolic acid, MW=55,000g/mol, purchased from Sigma Aldrich) with siRNA
(purchased from Dharmacon) was prepared in a DMSO:DMF:water solvent mixture (4:16:1)
and cast on a poly(ethylene teraphthalate) (PET) sheet (delivery sheet). The delivery sheet
was then placed in conformal contact with a PRINT mold with 80×320 nm features
patterned. The mold was kindly provided by from Liquidia Technologies (Product #
MCI-300-162B, 6” wide). The delivery sheet and mold were passed through a heated
laminator (150°C, 5.5 ×105 Pa) and separated at the nip. This process enables the siRNA/
polymer to fill the molds thereby forming nanoparticles. To harvest the nanoparticles from
the mold, the mold was placed in conformal contact with a PET sheet that was coated with a
layer (400 nm cast from water) of poly(vinyl alcohol) (PVA, MW=2000g/mol). The mold/
PET-PVA ensemble was again passed through the laminator (150°C, 5.5 ×105 Pa). Both the
filling of the mold and the transferring of the particles onto the PVA coated PET sheet were
performed at low humidity (~20–30%). The particles were then released from the PET/PVA
sheet by using a bead of water (~1mL) to dissolve the PVA layer thereby removing the
particles from the PET sheet. This process was accomplished using a simple bead harvester.
A 1 mg/mL stock solution of DOTAP:DOPE (1:1 wt%, purchased from Avanti Polar
Lipids) in water was used to release the particles from the PET sheet by dissolving the PVA
coating. Six feet of particles were harvested in 1 mL of 1 mg/mL lipid (1 mg of lipid for 6 ft
of particles – 0.17 mg lipid/ft of particles). The typical yield of particles was 0.4 mg
particles/ft of PRINT mold. Therefore 0.4 mg of particles was coated with 0.17 mg of lipid,
resulting in a particle to lipid mass ratio 1:2.4. To remove excess lipid and PVA and to
concentrate the particles, tangential flow filtration (TFF) was used to concentrate the particle
dispersion to a concentration of 2 mg/mL. The particles were then lyophilized by adding 10×
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mannitol and 8× sucrose (10× and 8× to mass of particles) using a tree lyophilizer. Mannitol
and sucrose were used as cryoprotectants. The ratio of particles produced to harvesting lipid
determines the zeta potential of the particles (Figure 1).
The particles were characterized using dynamic light scattering (DLS) (size and zeta
potential measurements) and both scanning electron microscopy (SEM) and transmission
electron microscopy (TEM) (Figure 2 and Table 1). PLGA particles that are harvested in
pure water were negatively charged (−4.9 mV), whereas the lipid-coated particles are
positively charged and the charge could be controlled over a wide range (0–20 mV). The
stability of the particles in PBS and serum was investigated at physiological conditions. As
seen in Figure S1, the size of the particles was found to be stable up to one week at at 37 °C
in phosphate buffer and 10% serum in phosphate buffer. PLGA is a biodegradable polymer
and so with time the polymer degrades into lactic acid and glycolic acid in water.
Interestingly, the zeta potential of the lipid-coated PLGA/siRNA particles was negative
when the particles were placed in 10% serum, suggesting the adsorption of serum proteins.
This result is not surprising because serum is composed of negatively charged proteins. The
release profile of the siRNA from the PLGA in PBS at 37 °C was determined by extracting
the siRNA from the remaining particle solution and running a 2.5% agarose gel (Figure S2).
In addition, the stability of the siRNA in the lipid-coated PLGA/siRNA particles in cell
culture media was evaluated by incubating the particles in cell culture media for 0, 0.5, 1, 4,
and 24 h at 37°C and extracting the siRNA and running a 2.5% agarose gel (Figure S3). The
siRNA bands in the agarose gel indicate that the siRNA is stable in the lipid-coated PLGA/
siRNA particles upto 24 h in cell culture media.
siRNA loading capacity of particles was examined by dissolving the particles in chloroform
and extracting siRNA with 0.1% SDS/0.5 M NaCl aqueous solution. When loaded on 2.5%
agarose gel, intact particles did not go into 2.5% agarose gel due to their size (Figure 3).
siRNA extracted with the above method formed sharp bands in gel, and was imaged and
quantified to be between 1–2 wt% siRNA in the particles. Thus the encapsulation efficiency
of this particle fabrication approach is between 20–40 % (1–2 wt% vs. 5 wt% charged),
which is in the range of encapsulation efficiencies for PLGA formulations (15–43%).29 By
using a PLGA with a lower molecular weight and different lactic acid to glycolic acid ratio
we were able to increase the encapsulation of siRNA (Table 2).
Cationic particles were found to be readily internalized into cells.30 Dye-labeled siRNA
(Alexafluorophore AF547) was used to evaluate the internalization of lipid-coated PLGA/
siRNA nanoparticles by various cell lines including: Raw264.7 (mouse macrophage), HeLa/
luc (human cervical cancer), PC3, DU145, LNCaP (all human prostate cancer), and HepG2
(human liver carcinoma). Figure 4 illustrates that these different types of cell lines were all
able to internalize the lipid-coated PLGA/siRNA particles. While HeLa/luc, PC3, DU145
and Raw264.7 cells showed very high uptake of particles, i.e.~100% of the cells were
particle-positive after 4 h dosing with 100 ug/mL of particles, LNCaP and HepG2 cells were
not very efficient in taking up particles because their doubling time is 60 h and 48 h
respectively which is significantly longer than the other cell lines (Table S1). The variation
in the kinetics of cellular uptake for the same type of nanoparticle on different cell lines has
been reported. Internalization of particles by multiple cell lines was further confirmed by
confocal microscopy (Figure 5). To confirm that the images in Figure 5 were not simply of
adsorbed versus internalized particles, a sample Z-stack image of the HeLa cells dosed with
100 µg/mL of lipid-coated PLGA/siRNA particles is included in Figure S4 which confirms
the particle internalization.
Luciferase-expressing HeLa (HeLa/luc) cells were used to test the efficacy of lipid-coated
PLGA/siRNA nanoparticle formulation to silence gene expression. HeLa/luc cells were
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dosed for 4 h with lipid-coated PLGA/siRNA particles (5 wt% luciferase or irrelevant
control siRNA and 95 wt% PLGA, coated with 0.17 mg DOTAP:DOPE per ft of PRINT
mold corresponding to 1:2 lipid:particle by mass) and incubated for 72 h. The cells
incubated with the particles containing the luciferase siRNA resulted a decrease in the
luciferase expression in comparison to the untreated cells, whereas the cells treated with the
particles that were loaded with the control sequence did not exhibit a decrease in the
luciferase expression. The half maximal inhibitory concentration (IC50) value of these
PRINT particle formulation (47 nM) was comparable to that of Lipofectamine 2000
transfection (55 nM) (Figure 6). Knockdown of luciferase expression can be achieved at 24
h and 48 h of incubation as well (Figure S5). The IC50 value of the particles could be varied
by varying the zeta potential of the particles (which can be varied by changing the lipid:
particle ratio) (Figure 7)). The higher the zeta potential, the lower IC50 was obtained.
However, cytotoxicity of particles also increased with zeta potential. We chose 0.17 mg/mL
(~+3 mV) as the appropriate lipid solution concentration because it resulted in a relatively
low IC50 value (47 nM) as well as minimal cytotoxicity at the highest concentration of
particles tested (200 ug/mL).
After demonstrating that the lipid-coated PLGA/siRNA particles were able to deliver
luciferase siRNA and knockdown luciferase expression, we further evaluated our
formulation with a therapeutically relevant siRNA target. KIF11 (also known as Eg5,
purchased from Dharmacon) encodes a motor protein that belongs to the kinesin-like protein
family that is involved in bipolar spindle formation during cell mitosis. KIF11 represents an
attractive anti-cancer target, and inhition of KIF11 is known to cause mitotic arrest and
apoptosis of multiple cancers.31–34 Three prostate cancer cell lines (LNCaP, PC3, and
DU145) were dosed with 100 µg/mL of lipid-coated PLGA particles carrying KIF11 siRNA
or irrelevant control siRNA for 4 h, followed by 72 h incubation in complete growth
medium. Quantitative RT-PCR results showed a statistically significant decrease in KIF11
mRNA level in all three prostate cancer cells lines dosed with KIF11 siRNA PLGA particles
while control siRNA-loaded particles did not show a decrease in KIF11 mRNA level (Figure
8A). The statistical analysis was done by comparing the knockdown of lipid-coated PLGA/
siRNA particles containing KIF11 siRNA and control siRNA using the Wilcoxon Rank test.
For all the three different cell lines the p value was < 0.01. Delivery of KIF11 siRNA by the
lipid-coated PLGA carrier also induced a significant decrease in the cell viability of the
three cell lines as shown by a CellTiter-Glo viability assay (Figure 8B). To confirm the
down regulation of KIF11 protein, Western Blot analysis was also performed (Figure S6).
Currently we are working on the in vivo delivery of siRNA for prostate cancer and other
targets.
Herein we have developed a process that enables the formation of a simple two-component
PLGA-siRNA nanoparticle system. The formation of a polyplex has been avoided using the
PRINT process and transfection achieved via surface modification of particles with lipids.
The internalization of PRINT lipid-coated PLGA/siRNA nanoparticles by multiple cancer
cell lines and the knockdown therapeutically relevant genes has been demonstrated. We are
now investigating the in vivo efficacy of lipid-coated PLGA-siRNA nanoparticles.
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The zeta potential of the particles can be varied by changing the lipid:particle ratio based on
the harvesting lipid concentration to particle concentration.
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A) SEM image of lipid-coated PLGA/siRNA nanoparticles. B) TEM image of lipid-coated
PLGA/siRNA nanoparticles.
Hasan et al. Page 9














Determination of siRNA encapsulation. 1, 50 ng siRNA; 2, 100 ng siRNA; 3, 150 ng
siRNA; 4, 200 ng siRNA; 5, 20 µg lipid-coated PLGA/siRNA nanoparticles; 6–8, three
successive siRNA extractions from lipid-coated PLGA/siRNA nanoparticles with
chloroform/0.1% SDS-0.5M NaCl, equivalent to 20 µg particles. Samples were run on 2.5%
agarose gel and imaged with ImageQuant LAS4000 (GE Healthcare).
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Cellular internalization of lipid-coated particles. Cells were dosed with 80×320 nm particles
loaded with Alexa Fluor 547 labeled siRNA at 50 µg/mL for 4 h. Then particles were
removed and cells were washed 3 times with PBS. Trypsinized cells were analyzed by a
Cyan ADP flow cytometer (Dako). Cell uptake was expressed as percentage of cells that
were fluorescence positive.
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Cellular internalization of lipid-coated PLGA/siRNA particles by confocal microscopy.
Cells were treated with 100 µg/mL particles loaded with Alexa Fluor 547 conjugated siRNA
for 4 h at 37°C. Cells were then fixed and stained with Alexa Fluor 488 labelled phalloidin.
All the images are on the same scale. The brightness of the confocal images was enhanced.
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Knockdown of luciferase gene expression in HeLa/luc cells using lipid-coated PLGA/
siRNA nanoparticles with (A) antiluciferase siRNA, (B) control siRNA, and (C) transfection
of luciferase siRNA with Lipofectamine 2000.
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IC50 of luciferase gene knockdown on HeLa/luc cells by lipid-coated PLGA particles can be
tuned by changing the zeta potential of nanoparticles.
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Delivery of therapeutic siRNA to prostate cancer cells. Cells were dosed with particles for 4
h at 37°C, followed by 72 h incubation in complete growth medium. qRT-PCR (top) and
CellTiter-Glo viability assay (promega) (bottom).
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Table 1
Particle characterization by dynamic light scattering.
Particle Size (nm) PDI Zeta potential (mV)
PLGA-siRNA 198 ± 3.45 0.045 ± 0.009 −3.45 ± 1.9
PLGA-siRNA-lipid
(0.2 mg lipid/ft particles)
207 ± 4.461 0.092 ± 0.005 5.29 ± 1.5
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Table 2
Encapsulation efficiency of siRNA in different types of PLGA.
Polymer Total siRNA (wt%) Encapsulation efficiency (%)
33K PLGA (50:50) 2.3 46
55K PLGA (85:15) 1.61 32
Nano Lett. Author manuscript; available in PMC 2013 January 11.
